These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 24619311

  • 1. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease.
    Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM.
    Immunol Res; 2014 May; 58(2-3):268-76. PubMed ID: 24619311
    [Abstract] [Full Text] [Related]

  • 2. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo.
    Murer A, Rühl J, Zbinden A, Capaul R, Hammerschmidt W, Chijioke O, Münz C.
    mBio; 2019 Jan 15; 10(1):. PubMed ID: 30647153
    [Abstract] [Full Text] [Related]

  • 3. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH, Wolf H, Minarovits J.
    Autoimmunity; 2008 May 15; 41(4):298-328. PubMed ID: 18432410
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
    Westhoff Smith D, Chakravorty A, Hayes M, Hammerschmidt W, Sugden B.
    mBio; 2021 Dec 21; 12(6):e0224321. PubMed ID: 34781735
    [Abstract] [Full Text] [Related]

  • 7. Role of Viral and Host microRNAs in Immune Regulation of Epstein-Barr Virus-Associated Diseases.
    Iizasa H, Kim H, Kartika AV, Kanehiro Y, Yoshiyama H.
    Front Immunol; 2020 Dec 21; 11():367. PubMed ID: 32194570
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.
    Forte E, Salinas RE, Chang C, Zhou T, Linnstaedt SD, Gottwein E, Jacobs C, Jima D, Li QJ, Dave SS, Luftig MA.
    J Virol; 2012 Jun 21; 86(12):6889-98. PubMed ID: 22496226
    [Abstract] [Full Text] [Related]

  • 11. B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.
    Chen Y, Fachko DN, Ivanov NS, Skalsky RL.
    mSphere; 2021 Apr 14; 6(2):. PubMed ID: 33853871
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
    Price AM, Messinger JE, Luftig MA.
    J Virol; 2018 Jan 15; 92(2):. PubMed ID: 29118124
    [Abstract] [Full Text] [Related]

  • 14. Current Trends and Alternative Scenarios in EBV Research.
    Minarovits J, Niller HH.
    Methods Mol Biol; 2017 Jan 15; 1532():1-32. PubMed ID: 27873264
    [Abstract] [Full Text] [Related]

  • 15. Immune Evasion by Epstein-Barr Virus.
    Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ.
    Curr Top Microbiol Immunol; 2015 Jan 15; 391():355-81. PubMed ID: 26428381
    [Abstract] [Full Text] [Related]

  • 16. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 17. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
    Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R.
    PLoS Pathog; 2012 Oct 18; 8(5):e1002704. PubMed ID: 22615564
    [Abstract] [Full Text] [Related]

  • 18. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.
    Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG.
    Blood; 2011 Jun 02; 117(22):5907-17. PubMed ID: 21411757
    [Abstract] [Full Text] [Related]

  • 19. Role of LMP1 in immune control of EBV infection.
    Pai S, Khanna R.
    Semin Cancer Biol; 2001 Dec 02; 11(6):455-60. PubMed ID: 11669607
    [Abstract] [Full Text] [Related]

  • 20. Latent membrane protein 1 and the B lymphocyte-a complex relationship.
    Stunz LL, Bishop GA.
    Crit Rev Immunol; 2014 Dec 02; 34(3):177-98. PubMed ID: 24941072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.